Trade

with

Salix Pharmaceuticals Ltd
(NASDAQ: SLXP)
AdChoices
135.56
-2.05
-1.49%
After Hours :
135.59
+0.03
+0.02%

Open

138.53

Previous Close

137.61

Volume (Avg)

1.29M (1.83M)

Day's Range

135.09-140.25

52Wk Range

70.64-172.98

Market Cap.

8.63B

Dividend Rate ( Yield )

-

Beta

1.10

Shares Outstanding

63.69M

P/E Ratio (EPS)

149.25 (0.90)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 933.84M

    • Net Income

    • 143.03M

    • Market Cap.

    • 8.63B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 4.67

    • PEG (Price/Earnings Growth) Ratio

    • 0.65

    • Beta

    • 1.10

    • Forward P/E

    • 20.83

    • Price/Sales

    • 7.01

    • Price/Book Value

    • 11.72

    • Price/Cash flow

    • 48.54

      • EBITDA

      • 325.85M

      • Return on Capital %

      • 1.74

      • Return on Equity %

      • 8.70

      • Return on Assets %

      • 1.74

      • Book Value/Share

      • 11.56

      • Shares Outstanding

      • 63.69M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 162.83

        • Credit Rating

        • -

        • Analysts

        • 6

        • EPS Estimate

        • 4.36

        • Cashflow Estimate

        • 8.17

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 62.20

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • 122.60

          • -26.33

          • Net Income

            Q/Q (last year)

          • -84.40

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 39.19

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 74.67

            • 64.72

            • Pre-Tax Margin

            • 5.43

            • 13.77

            • Net Profit Margin

            • 4.67

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 80.70

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 5.40

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 2.70

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 3.32

              • 0.33

              • Current Ratio

              • 1.52

              • 1.52

              • Quick Ratio

              • 0.99

              • 0.87

              • Interest Coverage

              • 1.59

              • 6.77

              • Leverage Ratio

              • 6.54

              • 1.91

              • Book Value/Share

              • 11.56

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 156.25

                • 65.36

                • P/E Ratio 5-Year High

                • 191.32

                • 237.47

                • P/E Ratio 5-Year Low

                • 20.11

                • 19.71

                • Price/Sales Ratio

                • 7.34

                • 3.63

                • Price/Book Value

                • 12.29

                • 3.39

                • Price/Cash Flow Ratio

                • 48.54

                • 21.83

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 8.70

                    (6.20)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • 1.74

                    (1.00)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • 6.13

                    (-1.40)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • 66.52k

                  • 27.79k

                  • Inventory Turnover

                  • 2.56

                  • 1.80

                  • Asset Turnover

                  • 0.37

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  271.71M
                  Operating Margin
                  29.10
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  48.54
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  53.75%

                  Mutual Fund Ownership

                  58.80%

                  Float

                  72.30%

                  5% / Insider Ownership

                  2.70%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Health Care Fund

                  •  

                    1,824,545

                  • -10.25

                  • 2.87

                  • CREF Stock

                  •  

                    1,755,504

                  • 39.37

                  • 2.76

                  • Fidelity® Select Health Care Portfolio

                  •  

                    1,050,000

                  • 5.00

                  • 1.65

                  • Federated Kaufmann Fund

                  •  

                    1,000,000

                  • -16.67

                  • 1.57

                  • Vanguard Total Stock Mkt Idx

                  •  

                    988,526

                  • 1.20

                  • 1.55

                  • iShares Core S&P Mid-Cap (AU)

                  •  

                    869,897

                  • 0.07

                  • 1.20

                  • iShares Nasdaq Biotechnology

                  •  

                    827,041

                  • -0.24

                  • 1.14

                  • Vanguard Extended Market Index Fund

                  •  

                    582,534

                  • -1.42

                  • 0.91

                  • SPDR® S&P MIDCAP 400 ETF

                  •  

                    571,921

                  • -7.34

                  • 0.90

                  • Vanguard Explorer Fund

                  •  

                    546,641

                  • -37.59

                  • 0.86

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    7,058,551

                  • -0.23%

                  • 11.12

                  • Fidelity Management and Research Company

                  •  

                    5,931,338

                  • -17.76%

                  • 9.34

                  • Vanguard Group, Inc.

                  •  

                    3,910,354

                  • -5.10%

                  • 6.16

                  • BlackRock Fund Advisors

                  •  

                    2,673,206

                  • +2.89%

                  • 4.21

                  • TIAA-CREF Investment Management LLC

                  •  

                    1,996,458

                  • +72.59%

                  • 3.14

                  • State Street Corp

                  •  

                    1,916,718

                  • +0.96%

                  • 3.02

                  • Columbia Mangmt Investment Advisers, LLC

                  •  

                    1,604,246

                  • -4.47%

                  • 2.53

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Aggressive Growth

                  Style

                  Mid Growth

                  Salix Pharmaceuticals Ltd is a Delaware corporation incorporated on December 1993. The Company is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used i...moren the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract. The Companys search and development efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. Its products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active...more ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by noninvasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, lowvolume liquid bowel prep with the effectiveness of highvolume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. AnusolHC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The Company mainly sells its products to pharmaceutical wholesalers. The Company uses third party manufacturers to produce its products. The research, testing, manufacture, marketing and distribution of drug products are extensively regulated by governmental authorities in the United States and other countries.lessless

                  Key People

                  Carolyn J. Logan

                  CEO/Director/President

                  Mr. Thomas W. D'Alonzo

                  Chairman of the Board/Director

                  Adam C. Derbyshire

                  CFO/Chief Accounting Officer/Executive VP, Divisional

                  Dr. William P. Forbes

                  Executive VP, Divisional/Other Executive Officer

                  Mr. Rick D. Scruggs

                  Executive VP, Divisional

                  • Salix Pharmaceuticals Ltd

                  • 8510 Colonnade Center Drive

                  • Raleigh, NC 27615

                  • USA.Map

                  • Phone: +1 919 862-1000

                  • Fax: +1 919 862-1095

                  • salix.com

                  Incorporated

                  1993

                  Employees

                  887

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: